Navigation Links
FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
Date:4/23/2008

July 2007, the product has achieved a U.S. market share of 6.9 percent based on weekly branded prescription volume VYVANSE formulary coverage has been positive, with the top six managed care plans now covering the product in a preferred formulary position.

VYVANSE is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of VYVANSE to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in normal GI transit times.

VYVANSE is currently available in three dosage strengths of 30 mg, 50 mg and 70 mg, each for once-daily dosing. Additional dosage strengths of 20 mg, 40 mg and 60 mg VYVANSE have also been FDA-approved and are expected to be available in pharmacies this summer.

Additional information about VYVANSE and Full Prescribing Information are available at www.vyvanse.com.

VYVANSE Significantly Improved ADHD Symptoms

The phase III pivotal trial that led to the FDA approval of VYVANSE to treat adults with ADHD was a double-blind, placebo-controlled, four-week study with dose escalations in 414 adults aged 18 to 55 years. In this study, adults with ADHD experienced significant improvements in ADHD symptom control within one week of treatment with once-daily VYVANSE.

Treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) was significantly more effective than placebo, providing a reduction in ADHD Rating Scale (ADHD-RS-IV) scores ranging from 16.2 to 18.6 points at endpoint. The ADHD-RS-IV is a standardized test for assessing symptoms of ADHD and for assessing their response to treatment. This scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the APAs Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, a pu
'/>"/>

Contact: Matthew Cabrey, Shire
484-595-8248
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Amada Senior ... a new office in the greater Phoenix area – their Mesa, Arizona location ... to senior care with their purchase of the rights to the area after years ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... to healthcare providers, has been retained to lead a national chief executive ... top executive search firms in the healthcare industry, B. E. Smith has recently ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Research published ... Kit (Peek) smartphone app to test eyesight was just as accurate as those from ... of Hygiene and Tropical Medicine is responsible for the development of the test, which ...
(Date:7/1/2015)... ... ... The Recovery Workforce Summit: 2015 PRA Annual Conference , presented by PRA ... a keynote on June 2nd in Philadelphia, PA. Stossel led a timely keynote address ... and reach to the essential message, while opening doors to wellness and recovery. Stossel ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... and approaches to case management, placement, sober companionship and delivery to wilderness therapy ... to working with and transporting clients with anxiety, ADHD, autism spectrum disorders, eating ...
Breaking Medicine News(10 mins):Health News:Amada Senior Care Expands to Greater Phoenix Area 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 2Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 3Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 2Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 3Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 4Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 5Health News:All Kinds of Therapy – Announces New Partnership Feature, Therapeutic Experts 2
... treated in many cases, say US doctors. In peripheral artery ... blocked with the same kind of fatty deposits - plaque ... treating it is very simple - keep walking. While the ... ability to walk with ease. Positive effects are seen within ...
... Black Death during middle ages in Europe and now ... sequenced. The genes seem to be "unusually fluid", readily ... microbes. ,That could mean that more virulent strains of ... strains might be relatively easy to develop as weapons. ...
... ingredient in the -- depo medroxyprogesterone acetate or DMPA -- ... younger you are when you begin using this contraceptive, the ... // ,From the time we are born, ... down and re-building, usually in a well-balanced design that keeps ...
... pregnant women stopped smoking, say Australian researchers, arguing that healthcare ... quit.,They found that smoking doubles the risk of having a ... and triples the rate of SIDS - and if women ... cut their smoking by half to achieve any benefit for ...
... pressure on the nerves exiting the spine may lead ... the way your spine is aligned. The World Chiropractic ... on the nerves that exit the spine. And this ... ,The chiropractors call these misalignments and neurology problems ...
... the risk of a gastrointestinal bleed in older patients. ... of antidepressants which are very widely prescribed. They are ... of side effects. But, as Researchers at Ottawa Hospital ... ,Almost 314,000 patients aged 65 ...
Cached Medicine News:Health News:Sequencing of the Plague 2
(Date:7/1/2015)... 2015  AVACEN, Inc. announced today the issue by the ... medical technology platform supporting its unique Dry Heat Therapy AVACEN ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... 9,066,781 - Methods And Apparatus For Therapeutic Application of Thermal ... methods of use, referred to by the company as the ...
(Date:7/1/2015)... 1, 2015 Radiant Insights announce ... Oxygen Concentrators Market Shares, Strategy, and Forecasts, Worldwide, ... continuing growth as the aging population worldwide needs homecare ... conditions where oxygen is able to improve the quality ... have become affordable and support a mobile lifestyle even ...
(Date:7/1/2015)... , July 1, 2015 ... is expected to reach USD 49,119.2 million by 2020, ... Inc. Monitoring services is expected to remain the dominant ... USD 1,227.5 million in 2012, and an estimated CAGR ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , Browse full ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 3Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5
... following statement,by Andrea Kavanagh, Director of the Pure Salmon ... publish a study tomorrow that,shows sea lice from open ... wild fish stocks., "This study confirms what we ... havoc on wild salmon populations. If outbreaks of these,parasites ...
... Results, SOUTH SAN FRANCICSO, Calif., Dec. 13 ... announced that its oral syk,kinase inhibitor, R788 (tamatinib ... Arthritis (RA) patients in a,recently completed Phase 2 ... 150mg po bid (orally, twice daily), showed higher ...
Cached Medicine Technology:Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 2Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 3Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 4Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 5Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: